Blood Testing Market Size, Share and Growth Outlook, 2026

Blood Testing Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Blood Testing Market size is forecast to increase from $118.33 Billion in 2026 to $237.52 Billion in 2034 at a CAGR of 9.1% between 2026 and 2034.

The Blood Testing market report provides detailed analysis and outlook of Blood Testing segments including By Test Type (Clinical Chemistry, Infectious Disease Testing, Hematology, Cancer Biomarker, Immunological & Autoimmune Disease Testing, Blood Clotting ), By Product Type (Reagents and Kits, Instruments, Software and Services), By Technology (Immunoassays, Molecular Diagnostics, Next-Generation Sequencing, Mass Spectrometry & Chromatography, Flow Cytometry), By Method (Automated Blood Testing, Manual ), By End-User (Hospitals and Clinics, Diagnostic Laboratories, Blood Banks, Research Institutes and Academia, Home Care and Self-Testing Users) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Blood Testing Industry Overview

Advancements in Blood-Based Diagnostics Transforming Healthcare Delivery

The blood testing industry remains a cornerstone of modern healthcare, supporting disease detection, patient monitoring, preventive screening, and precision medicine initiatives across clinical settings. Growing demand for early disease diagnosis, personalized healthcare, and digitally connected diagnostic services is driving significant innovation in blood testing technologies. Healthcare providers, diagnostic laboratories, and biotechnology companies are increasingly investing in advanced testing platforms that improve diagnostic accuracy, enhance patient accessibility, and streamline data integration. The industry is also benefiting from expanding applications of molecular diagnostics, liquid biopsy technologies, and digital health ecosystems that enable more proactive and patient-centered care.

Multi-Cancer Early Detection Tests Expanding Clinical Applications

A major trend shaping the blood testing industry is the advancement of blood-based multi-cancer early detection technologies. In May 2026, GRAIL announced that data from its PATHFINDER 2 clinical study demonstrated improved cancer detection rates when its blood-based multi-cancer early detection test was used alongside existing standard-of-care screening methods. The study highlighted the potential of blood-based screening approaches to identify cancers that may otherwise remain undetected through conventional screening programs. The findings are currently being utilized to support regulatory submissions aimed at broader clinical adoption. The growing validation of multi-cancer early detection testing is strengthening the role of blood diagnostics in preventive oncology and population health management.

Digital Health Integration Enhancing Patient Data Accessibility

The blood testing industry is increasingly aligned with healthcare digitization initiatives that emphasize patient engagement and data portability. In April 2026, Quest Diagnostics introduced a new feature within its patient-facing mobile application that enables individuals to directly integrate blood test results with Apple Health and other third-party electronic health record platforms. This development reflects the growing demand for seamless access to personal health information and supports more coordinated healthcare management. Enhanced interoperability between diagnostic platforms and digital health ecosystems allows patients and healthcare providers to access laboratory data more efficiently, improving clinical decision-making and supporting longitudinal health monitoring.

Regulatory Changes Reshaping Diagnostic Test Development

The regulatory landscape for blood testing is evolving significantly with increased oversight of diagnostic assays. In early 2026, the U.S. Food and Drug Administration finalized its policy to phase in regulation of most laboratory-developed tests. This policy shift requires diagnostic laboratories to comply with premarket review processes and quality system regulations, fundamentally impacting how blood-based diagnostic assays are validated, developed, and commercialized. The new framework is expected to strengthen quality assurance, improve analytical reliability, and enhance patient confidence in diagnostic testing. As laboratories adapt to these requirements, regulatory compliance is becoming an increasingly important factor influencing innovation and market access within the blood testing industry.

Blood Testing Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Blood Testing market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Roche Diagnostics , Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation , Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Sysmex Corporation, Becton, Dickinson and Company , QuidelOrtho Corporation, Horiba, Ltd.. The Blood Testing market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Blood Testing industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Blood Testing Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Blood Testing companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Blood Testing markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Blood Testing Market Competitive Benchmarking and Company Analysis

Leading companies in Blood Testing industry include- Roche Diagnostics , Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation , Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Sysmex Corporation, Becton, Dickinson and Company , QuidelOrtho Corporation, Horiba, Ltd.. The Blood Testing market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Blood Testing Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Blood Testing market remains one of the strongest-performing segments in the country.
The US Blood Testing Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Blood Testing market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Blood Testing industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Blood Testing markets

Canada's strong Blood Testing sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Blood Testing market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Blood Testing Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Blood Testing market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Blood Testing population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Blood Testing industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Blood Testing market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Blood Testing sales through 2034

France Blood Testing companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Blood Testing Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Blood Testing distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Blood Testing Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Blood Testing market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Blood Testing industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Blood Testing industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Blood Testing Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Blood Testing market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Blood Testing market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Blood Testing Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Blood Testing Market Segmentation

By Test Type
Clinical Chemistry
Infectious Disease Testing
Hematology
Cancer Biomarker
Immunological & Autoimmune Disease Testing
Blood Clotting
By Product Type
Reagents and Kits
Instruments
Software and Services
By Technology
Immunoassays
Molecular Diagnostics
Next-Generation Sequencing
Mass Spectrometry & Chromatography
Flow Cytometry
By Method
Automated Blood Testing
Manual
By End-User
Hospitals and Clinics
Diagnostic Laboratories
Blood Banks
Research Institutes and Academia
Home Care and Self-Testing Users

Top Companies in Blood Testing Industry

Roche Diagnostics
Abbott Laboratories
Siemens Healthineers AG
Danaher Corporation
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Sysmex Corporation
Becton, Dickinson and Company
QuidelOrtho Corporation
Horiba, Ltd.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025